Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) EBT Margin (2020 - 2024)

Goldenwell Biotech's EBT Margin history spans 5 years, with the latest figure at 43015.82% for Q4 2024.

  • For Q4 2024, EBT Margin fell 3501621.0% year-over-year to 43015.82%; the TTM value through Sep 2025 reached 12900.63%, up 1838759.0%, while the annual FY2024 figure was 94602.88%, 8821067.0% down from the prior year.
  • EBT Margin reached 43015.82% in Q4 2024 per GWLL's latest filing, down from 35913.67% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 10.49% in Q3 2022 to a low of 43015.82% in Q4 2024.
  • Average EBT Margin over 5 years is 9487.9%, with a median of 2920.0% recorded in 2020.
  • Peak YoY movement for EBT Margin: skyrocketed 604653bps in 2023, then crashed -3501621bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 2920.0% in 2020, then soared by 79bps to 602.28% in 2021, then skyrocketed by 98bps to 10.49% in 2022, then tumbled by -76144bps to 7999.62% in 2023, then plummeted by -438bps to 43015.82% in 2024.
  • Per Business Quant, the three most recent readings for GWLL's EBT Margin are 43015.82% (Q4 2024), 35913.67% (Q2 2024), and 7999.62% (Q4 2023).